期刊文献+

四联疗法治疗根除幽门螺杆菌感染疗效观察 被引量:4

The effects of quadruple regimens for the treatment on helicobacter pylori infection
下载PDF
导出
摘要 目的应用四联疗法2周治疗消化性溃疡及慢性胃炎合并H.pylori感染患者疗效。方法患者均经胃镜及C14UBT检查,明确诊断后应用埃索美拉唑镁肠溶片20mg2次/d+胃三联片2次/d口服治疗2周为1个疗程,疗程结束后4周复查C14UBT检查。结果300例患者中消化性溃疡患者为138例、慢性胃炎患者为162例,疗程结束后有281例复查C14UBT,H.pylori感染根除率为91.1%(256/281),消化性溃疡患者与慢性胃炎患者H.pylori感染根除率经统计学处理差异无统计学意义(92.3%比90%)。结论四联疗法在临床上治疗H.pylori感染的疗效确切、费用低、不良反应轻,是理想的根除H.pylori的方法之一。 Objective To study the effect of quadruple regimens for two weeks on the treatment of peptic ulcer and chronic gastritis in combination with H. Pylori infection. Methods Patients with gastroendoscopy and ^14C- urea breath testing (^14C-UBT) confirmed helicobacter pylori infection were administered with esomeprazole 20 mg twice a day. And Weisanlian twice a day (per os) for two weeks. ^14C-UBT examination was carried after cessation of the treatment. Results Among the 300 patients, 138 cases were with peptic ulcer and 162 cases were with chronic gastritis. H. pylori status was assessed by the ^14C-UBT in 281 patients. H. pylori eradication rate was 91.1% (256/281). There was no statistical difference of H. pylori eradication rate between the peptic ulcer and chronic gastritis (92. 3% vs 90% ). Conclusion The efficacy of quadruple therapy for H. Pylori infection is sure with low cost and no significant side effects. It is a ideal method for H. pylori eradication.
作者 李坚
出处 《中国现代药物应用》 2008年第23期22-24,共3页 Chinese Journal of Modern Drug Application
关键词 幽门螺杆菌 埃索美拉唑镁肠溶片 胃三联片 Helicobacter pylori Esomeprazole Weisanlian
  • 相关文献

参考文献7

二级参考文献23

  • 1Malfertheiner P, Mégraud F, O Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther,2002,16:167-180.
  • 2Mégraud F, Hazell S, Glupczynski Y. Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL, eds.Helicobacter pylori: Physiology and Genetics. Washington DC:ASM Press,2001. 511-530.
  • 3Mégraud F. Helicobacter pylori and macrolides. In: Schonfeld W, Kirst HA, eds. Macrolide antibiotics. Berlin: Birkhauser,2002. 243-260.
  • 4Gisbert JP, Calvet X, Bujanda L, et al. Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures.Helicobacter, 2003,8: 90-94.
  • 5Masconi G, Parente F, Russo A, et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol, 2001,96: 359-366.
  • 6Baena JM, Lopez C, Hidalgo A, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol, 2002,14: 291-296.
  • 7Amieva MR, Salama NR, Tompkins LS, et al. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol, 2002,4 : 677-690.
  • 8Matysiak-Budnik T, Heyman M, Candalh C, et al. In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier. J Antimicrob Chemother, 2002,50: 865-872.
  • 9Rabelo-Goncalves EM, Nishimura NF, Zeitune JM. Acute inflammatory response in the stomach of BALB/c mice chal lenged with coccoidal Helicobacter pylori. Mem Inst Oswaldo Cruz,2002,97:1201-1206.
  • 10Broutet N, Tchamgoué S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy. Results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther, 2003,17:99-109.

共引文献177

同被引文献29

  • 1薛美,任永强.两种方法治疗十二指肠溃疡幽门螺杆菌感染的疗效及治疗费用比较[J].临床医学,2005,25(10):26-28. 被引量:3
  • 2蔺蓉,熊汉华,钱伟,丁震,侯晓华.不同年龄人群幽门腺、幽门螺杆菌胃内分布特点及其关系[J].中华消化杂志,2005,25(11):680-681. 被引量:16
  • 3冯志杰.根治幽门螺杆菌感染对胃食管反流病的影响[J].中国全科医学,2006,9(24):2021-2022. 被引量:9
  • 4Gisbert JP,Dominguez-Munoz A,Gishert JL,et a1.Eaomeprazole-based therapy in helicobacter pylori eradication:any effect by increasing the dose of esomeprazole or prolonging the treatment[J].Am J Gastroenterol,2005,100(9):1935-1940.
  • 5Miner P,Daridson S,Anders H,et al.Plasma concentration is much greater with Nexium than with omeprazole[J].Am J Gastroenterol,2006,101(2):404-405.
  • 6Wilder-Smith CH,Rohss K,Nilsson-Pieschl C,et a1.Esomeprarole 40 mg provides improved intragastrie acid control as ompared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers[J].Digestion,2003,68(4):184-188.
  • 7Gisbert JP,Dominguez-Munoz A,Gishert JL,et al.Eaomeprazole-b-ased therapy in helicobacter pylori eradication:any effect by increasing the dose of esomeprazole or prolonging the treatment[J].Am J Gastroenterol,2005,100(9):1935-1940.
  • 8Miner P,Daridson S,Anders H,et al.Eaomeprazole 40mg provides improved intragastrie acid control as compared with lansoprazole 30mg and rabepazole 20mg in healthy volunteers[J].Digestion,2003,68(4):184-188.
  • 9刘巍,姜黎,胡兴寿,夏冰.幽门螺杆菌相关性疾病及其防治[J].中国全科医学,2007,10(18):1563-1565. 被引量:23
  • 10中华医学会消化病学分会.幽门螺杆菌若干问题的共识意见.中华消化杂志,2004,24(2):126-127.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部